Evidence map›Paper›PMID 40461528›Full record

ArticleScientific reports2025

Pharmacokinetics of midazolam and hepatic cytochrome P450 3A activity in an in vivo extracorporeal membrane oxygenation rat model.

Yuhki Sato, Erina Motoishi, Rina Kakuba, Yuka Nagatsuka, Takuya Abe, Yutaka Fujii

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yuhki SatoDepartment of Pharmaceutical Sciences, Fukuyama University, Fukuyama-Shi, Hiroshima, Japan. s-yuhki@fukuyama-u.ac.jp.
Erina MotoishiDepartment of Pharmaceutical Sciences, Fukuyama University, Fukuyama-Shi, Hiroshima, Japan.
Rina KakubaDepartment of Pharmaceutical Sciences, Fukuyama University, Fukuyama-Shi, Hiroshima, Japan.
Yuka NagatsukaDepartment of Pharmaceutical Sciences, Fukuyama University, Fukuyama-Shi, Hiroshima, Japan.
Takuya AbeDepartment of Clinical Engineering and Medical Technology, Niigata University of Health and Welfare, Niigata-Shi, Niigata, Japan.
Yutaka FujiiDepartment of Clinical Engineering and Medical Technology, Niigata University of Health and Welfare, Niigata-Shi, Niigata, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Extracorporeal membrane oxygenation (ECMO) is increasingly being used in intensive care units. However, it can alter drug pharmacokinetics and lead to underexposure associated with treatment failure. The aim of the present study was to determine the influence of ECMO on the pharmacokinetics of midazolam (MDZ). An in vivo rat model was developed using a bolus injection of MDZ, with concentration monitoring for 180 min. Rats that underwent ECMO were compared with a control group. Pharmacokinetic analysis of in vivo data (noncompartmental analysis and nonlinear mixed effects modeling) was performed to determine the influence of ECMO. The activity of the enzyme CYP3A, which catalyzes MDZ metabolism was examined in the livers of ECMO-treated rats. In vivo pharmacokinetic models were developed, showing an increase in the volume of distribution and the area under the curve, but a decreased the clearance, which was associated with decreased CYP3A activity. These results suggest that ECMO may affect the efficacy or increase the risk of side effects associated with MDZ.

Indexed as

Cytochrome P-450 CYP3AExtracorporeal Membrane OxygenationLiverMidazolamAnimalsMaleRatsRats, Sprague-DawleyCytochrome P-450 CYP3AMidazolamECMOMidazolamPharmacokinetics

Identifiers

PMID40461528
PMCPMC12134156

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.